In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis
AUTOR(ES)
Alvirez-Freites, Enrique J.
FONTE
American Society for Microbiology
RESUMO
Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127120Documentos Relacionados
- In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
- In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis
- Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.
- In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
- In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.